Myelofibrosis (MF) is one of Ph negative myeloproliferative neoplasms (MPN). It could be present as primary myelofibrosis (PMF), post-polycythemia vera (post-PV) MF and post-essential thrombocythemia (post-ET) MF. JAK2V617F mutation is the common driver gene mutation of MF. Fedratinib is a secondary generation inhibitor of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway which have received approval by United States Food and Drug Administration (FDA) for the treatment of adult patients with International Prognostic Scoring System (IPSS) intermediate-2 or high-risk MF in August 2019, both as a first-line therapy or second-line therapy following first generation JAK/STAT signaling pathway inhibitor ruxolitinib intolerance or resistance. This article summarizes research progress of the pharmacological properties, mechanism of action, clinical efficacy, adverse reactions and drug resistance mechanism of fedratinib in the treatment of MF.
